Pemphigus: Study finds risk factors for relapse on rituximab
More research needed on optimal dosing schedule, investigators say
People with pemphigus with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, a study shows.
The findings come from a post-hoc analysis of the RITUX 3 trial, in which 90 patients were randomly assigned to 1000 mg IV rituximab at baseline and two weeks, followed by 500mg infusions at 12 and 18 months, plus short-term prednisone (0.5
